Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

A study on mice with melanoma found that aspirin lowered TXA2 levels, which freed up T cells and allowed them to fight cancer more effectively. However, the lead scientist stressed that long-term ...

Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent ...

Merck’s push to make Keytruda injectable has triggered a patent dispute with Halozyme. The conflict arises over the use of ...

Avoiding surgery for rectal cancer, Sarah Rack of Memphis traveled to Houston for treatment every three weeks for 18 months.

Tesla has its second straight difficult month in Germany, as data released Wednesday showed that vehicle registrations fell 76% in February in Europe's largest economy. The company has asked the U.S.

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Novo Nordisk plans to offer its Wegovy weight loss drug at a reduced cost of $499 per month for cash-paying customers in the ...

Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...

Merck (MRK) stock trended lower as Halozyme (HALO) challenges the company over injectable Keytruda patents. Read more here.